<unk>  has high affinity for the α2-adrenergic receptor, moderate affinity for the α1 receptor, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F, 5-HT2B, and dopamine D2 receptors, and weak affinity for the 5-HT1E, 5-HT2A, 5-HT5A, 5-HT7, and dopamine D3 receptors. It behaves as an antagonist at α1-adrenergic, α2-adrenergic, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, and dopamine D2, and as a partial agonist at 5-HT1A.<unk>  interacts with serotonin and dopamine receptors in high concentrations. +Pharmacologic profile Molecular target Binding affinity(Ki in nanomolar) Pharmacologic action Species Source SERT 1,000 Inhibitor Human Frontal cortex 5-HT1A 346 Partial agonist Human Cloned 5-HT1B 19.9 Antagonist Human Cloned 5-HT1D 44.3 Antagonist Human Cloned 5-HT1E 1,264 Unknown Human Cloned 5-HT1F 91.6 Unknown Human Cloned 5-HT2A 1,822 Antagonist Human Cloned 5-HT2B 143.7 Antagonist Human Cloned 5-HT7 2,850 Unknown Human Cloned α1A 1,680 Antagonist Human Cloned α1B 1,280 Antagonist Human Cloned α1C 770 Antagonist Human Cloned α1D 557 Antagonist Human Cloned α2A 1.05 Antagonist Human Cloned α2B 1.19 Antagonist Human Cloned α2C 1.19 Antagonist Human Cloned D2 339 Antagonist Human Cloned D3 3,235 Antagonist Human Cloned
Yohimbine
Acebutolol
Phenylephrine
Metergoline
Amiloride
Cyclothiazide
Prazosin
Moclobemide